<p>The biopharma industry is undergoing a "foundational reset," entering 2026 with positive momentum not seen in several years, a stark contrast to the outlook in 2025. While the first half of 2025 was plagued by policy overhang and uncertainty, a surge of activity in the second half created significant forward motion.</p>
<p>This renewed confidence is underpinned by key macroeconomic shifts, including the alleviation of policy concerns and the broad anticipation of a lower interest rate environment. This shift creates a significantly more favorable landscape for capital-intensive deal-making.</p>

<div class="intro-section" style="background-color: #f1f8ff; border: 1px solid #c8e1ff; padding: 20px; border-radius: 6px; margin-bottom: 24px;">
    <h4 style="margin-top: 0; margin-bottom: 12px;">Panelists</h4>
    <ul style="margin-bottom: 0; padding-left: 20px;">
        <li><strong>Roel van den Akkerm</strong>, Principal, US Pharmaceutical & Life Sciences Deals Leader, PwC US</li>
        <li><strong>Rachna Khosla</strong>, SVP, Head of Business Development, Amgen</li>
        <li><strong>Nicholas Donoghoe</strong>, EVP, Chief Business & Strategy Officer, AbbVie</li>
        <li><strong>Elizabeth Naldi-Jacob</strong>, VP & Head, HQ Transactions & Corporate Development, Merck</li>
        <li><strong>Moderator: John Carroll</strong>, Founder & Editor, Endpoints News</li>
    </ul>
</div>

<div class="image-container">
    <img src="assets/images/JPM-2026-dealmaking-forecast.png" alt="JPM 2026 Dealmaking Forecast Panel">
    <p class="image-caption">J.P. Morgan Healthcare Conference 2026 Panel</p>
</div>

<h3>The M&A Landscape: A Debate on Scale and Strategic Focus</h3>
<p>Mergers and acquisitions (M&A) remain a cornerstone of growth and innovation in the biopharma ecosystem. As companies look to replenish pipelines and access novel technologies, the current market is forcing a re-evaluation of corporate development philosophies. A central debate has emerged between pursuing large-scale, transformative mergers versus a high-velocity strategy of acquiring individual, high-value assets.</p>
<p>On one side, there is a clear appetite for continued large deals in the $10 billion-plus range. This approach allows companies to follow compelling science wherever it leads, even into new therapeutic areas. <strong>Merck’s</strong> recent acquisitions of Cidera and Verona—representing two separate transactions valued at $10 billion each—and its earlier entry into ophthalmology with the purchase of EyeBio, serve as clear evidence of this strategy.</p>
<p>Conversely, the current landscape is rich with a high volume of individual, innovative assets, making targeted acquisitions a prevalent trend. With an abundance of new modalities and a globalized innovation base, there are often too many attractive choices to necessitate massive consolidation. This philosophy is reflected in <strong>AbbVie's</strong> high-velocity approach, where the company completed over 20 deals in the past year alone.</p>

<table style="width:100%; border-collapse: collapse; margin: 20px 0; font-size: 15px;">
  <thead>
    <tr style="background-color: #f6f8fa; text-align: left;">
      <th style="padding: 12px; border: 1px solid #d0d7de;">Company</th>
      <th style="padding: 12px; border: 1px solid #d0d7de;">Core BD Philosophy</th>
      <th style="padding: 12px; border: 1px solid #d0d7de;">Key Supporting Evidence</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="padding: 12px; border: 1px solid #d0d7de;"><strong>Amgen</strong></td>
      <td style="padding: 12px; border: 1px solid #d0d7de;">Discipline-Driven & Complementary</td>
      <td style="padding: 12px; border: 1px solid #d0d7de;">Views BD as a complement to internal R&D, seeking "truly best-in-class" opportunities. BD historically represents ~50% of revenues.</td>
    </tr>
    <tr>
      <td style="padding: 12px; border: 1px solid #d0d7de;"><strong>Merck</strong></td>
      <td style="padding: 12px; border: 1px solid #d0d7de;">Science-Driven</td>
      <td style="padding: 12px; border: 1px solid #d0d7de;">Follows the best science regardless of price or therapeutic area (e.g., entering ophthalmology after a 10-year absence).</td>
    </tr>
    <tr>
      <td style="padding: 12px; border: 1px solid #d0d7de;"><strong>AbbVie</strong></td>
      <td style="padding: 12px; border: 1px solid #d0d7de;">High-Velocity Asset Aggregation</td>
      <td style="padding: 12px; border: 1px solid #d0d7de;">Focuses on a rapid pace of deal-making (>20 deals/year) fueled by the volume of high-quality opportunities.</td>
    </tr>
  </tbody>
</table>

<h3>The Global Nexus of Innovation: China and AI as Transformative Forces</h3>
<p>The sources of biopharma innovation are expanding beyond traditional geographic and technological boundaries. Panelists identified two forces as particularly transformative heading into 2026: the emergence of China as a core innovation hub and the accelerating integration of artificial intelligence (AI) into the R&D process.</p>

<h4>The Ascendancy of China</h4>
<p>China's role in the global biopharma landscape has undergone a dramatic evolution, offering a compelling dual value proposition. First, it is a vast source of new molecules. Second, it presents a core strategic challenge and opportunity for Western pharma by demonstrating a "different operating model" that can accelerate development to proof-of-concept with a significantly leaner cost structure.</p>

<div style="background-color: #e3f4f4; border-left: 4px solid #c4dfdf; padding: 16px; margin: 24px 0; border-radius: 4px;">
    The panellists highlighted China's ability to conduct trials and generate human data much faster than Western counterparts. This speed is often attributed to differing regulatory frameworks and operational environments. In the West, stringent animal welfare protocols (such as the use of mice models) and extensive patient rights protections can extend timelines significantly. Competing with China’s speed remains a challenge for Western companies bound by these stricter regulatory and ethical requirements.
</div>

<h4>Artificial Intelligence: A Catalyst for R&D Efficiency</h4>
<p>Alongside the geographic shift, a technological revolution is underway, with AI acting as the catalyst for an industry "renaissance moment." The integration of AI is a direct response to unsustainable R&D costs and timelines. Its application is moving well beyond initial use cases in drug discovery and target identification; it is now being leveraged across a broader range of functions to accelerate development timelines and streamline regulatory pathways.</p>

<h3>The Art of the Deal: Creative Structuring</h3>
<p>Current market dynamics are fostering intense competition for high-value assets, compelling deal-makers to embrace creative and flexible deal structures. A primary driver of this trend is the subdued IPO market. With initial public offerings being a less viable exit path, acquisition has become the primary route to deliver investor returns.</p>
<p>In this environment, key mechanisms include:</p>
<ul>
    <li><strong>Contingent Value Rights (CVRs):</strong> A financial tool where the buyer promises to pay additional funds only if the acquired drug or technology meets specific milestones (e.g., FDA approval or sales targets). This helps bridge valuation gaps between buyer and seller.</li>
    <li><strong>Equity Stakes:</strong> Offering an equity position in a partnership provides an upside for the seller while aligning long-term interests.</li>
  </ul>
<p>Sellers are demonstrating significantly greater openness to CVRs than in the recent past. This willingness allows buyers to manage risk while offering a competitive total valuation.</p>

<h3>Strategic Focus: The Pursuit of Transformative and Curative Therapies</h3>
<p>A clear strategic pivot is underway, driven by increased payer scrutiny and the need to demonstrate overwhelming value propositions. The industry is shifting focus away from assets offering incremental improvements and toward those with the potential for transformative or curative outcomes.</p>
<p> Panellists highlighted several fields expected to be hot for deal-making in 2026:</p>
<ul>
    <li><strong>In situ CAR T:</strong> Viewed as transformative for autoimmune diseases, offering the potential for an "immune reset" with a single treatment paradigm.</li>
    <li><strong>siRNA:</strong> Noted for its ability to provide "very long, durable benefits," representing a significant leap forward in managing chronic conditions.</li>
    <li><strong>Neuroplastic Agents:</strong> Highlighted for their potential to help patients with psychiatric disorders achieve long-term benefits from limited dosing.</li>
    <li><strong>Rare Diseases:</strong> Continued high interest in areas where significant unmet needs remain.</li>
</ul>

<div style="background-color: #e3f4f4; border-left: 4px solid #c4dfdf; padding: 16px; margin: 24px 0; border-radius: 4px;">
    In my opinion, while siRNA is garnering attention, protein degraders (such as <strong>PROTACs</strong> or molecular glues) may hold superior potential. For siRNA to deliver long and durable benefits, delivery mechanisms remain a hurdle; while GalNAc conjugates work well for the liver, other tissues often require viral vectors or complex lipid nanoparticles, which can present toxicity issues. PROTACs may offer a more versatile small-molecule approach.
</div>

<h3>Regulatory Outlook and Conclusion</h3>
<p>The outlook for biopharma deal-making in 2026 is bolstered by a consensus that the external environment will be constructive. With the Federal Reserve likely shifting toward lower interest rates, it is becoming financially attractive for large companies to fund multi-billion dollar M&A activity.</p>
<p>In conclusion, the biopharma sector is poised for a dynamic 2026. This optimism is based on the convergence of powerful trends:</p>
<ul>
    <li>The accelerating pace of AI integration is making R&D more efficient.</li>
    <li>A wealth of high-quality science progressing through clinical development.</li>
    <li>A renewed focus on curative therapies in areas of high unmet need.</li>
</ul>
<p>Ultimately, strategic success in 2026 will be defined by the ability to globally source transformative science, leverage technology to accelerate development, and creatively structure deals to secure the assets that will define the next decade of medicine.</p>
<br/>
